Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
Phase 2
86
about 6.5 years
18+
1 site in UT
What this study is about
Researchers are testing whether nicotinamide helps prevent new non-melanoma skin cancers (NMSC) in people with chronic lymphocytic leukemia (CLL). Participants will take either nicotinamide or a placebo for two years. The trial will stop if there's no difference between the groups, meaning that nicotinamide doesn't help prevent NMSCs.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Nicotinamide
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
nicotinamide
Secondary: frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0 and iwCLL), seriousness, duration, and relationship to study treatment, objective response rate (the proportion of subjects achieving a CR or PR) and complete response rate as calculated per International Workshop on CLL (IWCLL) 2018 Criteria at Month 6, 12, 18, and 24, objective response rate (the proportion of subjects achieving a complete response [CR] or partial response [PR]) and complete response rate as calculated per International Workshop on CLL (IWCLL) 2018 Criteria at Month 6, 12, 18, and 24
Oncology